Efek Penggunaan Antikoagulan Dalam Menurunkan Kematian Pasien Covid-19 Di Rumah Sakit: Literature Review
Abstract
Introduction: The incidence of coagulopathy is one out of many cause of death due to endothelial damage caused by hyperinflammatory state in COVID-19 patients. COVID-19 treatment guidelines by the Indonesian Association of Pulmonary, Cardiovascular, and Internal Medicine Doctors widely recommend the use of anticoagulants in hospitalized COVID-19 patients even though there is no evidence of thrombosis or only suspected thrombosis by looking at the contraindication. This literature review was conducted to analyze the effect of anticoagulant use on mortality in hospitalized COVID-19 patients.
Keywords: Anticoagulant, coagulopathy, COVID-19, mortality
Abstrak
Salah satu penyebab kematian pasien COVID-19 adalah kejadian koagulopati dengan manifestasi trombosis akibat dari kerusakan endotel oleh keadaan hiperinflamasi pada pasien COVID-19. Pedoman tatalaksana COVID-19 yang disusun oleh Perhimpunan Dokter Paru, Kardiovaskuler, dan Penyakit Dalam Indonesia merekomendasikan penggunaan antikoagulan pada pasien COVID-19 yang dirawat di rumah sakit, meskipun tidak terlihat adanya trombosis maupun baru dicurigai trombosis dengan mempertimbangkan kontraindikasi pada pasien. Tinjauan literatur ini dilakukan untuk menganalisis pengaruh penggunaan antikoagulan terhadap mortalitas pasien COVID-19 dengan risiko koagulopati.
Kata Kunci: Antikoagulan; COVID-19; koagulopati; mortalitasFull Text:
PDFReferences
Albani F, Sepe L, Fusina F, Prezioso C, Baronio M, Caminiti F, et al. Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study. EClinicalMedicine [Internet]. 2020 Oct 1 [dikutip 12 Juli 2021];27:100562. Tersedia dari: https://linkinghub.elsevier.com/retrieve/pii/S2589537020303060
Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis [Internet]. 2020;50(1):72–81. Tersedia dari: https://doi.org/10.1007/s11239-020-02138-z
Baumann Kreuziger L, Y. Y. Lee A, Garcia D, Et.al. COVID-19 and VTE-Anticoagulation - Hematology.org [Internet]. American Society of Hematology. 2021 [dikutip 18 nov 2021]. Tersedia dari: https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation
Burhan E, Susanto AD, Isbaniah F, Nasution SA, Ginanjar E. 2020. PEDOMAN TATALAKSANA COVID-19.
Djoerban Z, Rasmin M, Kamsul Arif S, Haris S. Rekomendasi IDI Pemberian Antikoagulan Profilaksis Pada Pasien COVID-19 yang Dirawat di Rumah Sakit. 2020;
Gómez-Mesa J, Galindo-Coral S, … MM-C problems in, 2020 undefined. Thrombosis and Coagulopathy in COVID-19. Elsevier [Internet]. [dikutip 12 Juli 2021]; Tersedia dari: https://www.sciencedirect.com/science/article/pii/S0146280620302188
Hippensteel JA, LaRiviere WB, Colbert JF, Langou t-Astri CJ, Schmidt EP. Heparin as a therapy for COVID-19: Current evidence and future possibilities. Am J Physiol - Lung Cell Mol Physiol. 2020;319(2):L211–7.
Ho FK, Petermann-Rocha F, Gray SR, Jani BD, Vittal Katikireddi S, Niedzwiedz CL, et al. Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. PLoS One [Internet]. 2020 Nov 1 [dikutip14 Nov 2021];15(11 November):e0241824. Tersedia dari: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0241824
Iba T, Levy J, Levi M, and JT-J of T, 2020 undefined. Coagulopathy in COVID‐19. Wiley Online Libr [Internet]. [dikutip 12 Juli 2021];18(9):2103–9. Tersedia Pada: https://onlinelibrary.wiley.com/doi/abs/10.1111/jth.14975
Ionescu F, Grasso-Knight G, Castillo E, Naeem E, Petrescu I, Imam Z, et al. 2020. Therapeutic Anticoagulation Delays Death in COVID-19 Patients: Cross-Sectional Analysis of a Prospective Cohort. TH Open. 2020 Jul;04(03):e263–70.
Ionescu F, Jaiyesimi I, Petrescu I, Lawler PR, Castillo E, Munoz-Maldonado Y, et al. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis. Eur J Haematol [Internet]. 2021 Feb 1 [dikutip 19 Juni 2021];106(2):165–74. Tersedia dari: https://onlinelibrary.wiley. com/doi/abs/10.1111/ejh.13533
Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19 [Internet]. Intensive Care Medicine Springer; Aug 1, 2020 p. 1603–6. Tersedia dari: https://link.springer.com/article/10.1007/s00134-020-06088-1?fbclid=IwAR0qmLQDCh3n_VFRMa5Q-zJP-9bK0aBHv_D31ylVmjQl_HxQust9pDUHNZ0
Kamel AM, Sobhy M, Magdy N, Sabry N, Farid S. 2021. Anticoagulation outcomes in hospitalized Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies. Rev Med Virol. 2021 May;31(3):e2180.
Keputusan Menteri Kesehatan Republik Indonesia. 2021. Keputusan menteri kesehatan republik indonesia nomor hk.01.07/menkes/5671/2021 tentang manajemen klinis tata laksana. 2021 p. 1–106.
Liu H, Hu T, Zhang C, Chen X, … SZ-AJ of, 2021 . Mechanisms of COVID-19 thrombosis in an inflammatory environment and new anticoagulant targets. ncbi.nlm.nih.gov [Internet]. [dikutip 2021 Jul 12]; Tersedia dari: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205677/
Mucha SR, Dugar S, McCrae K, Joseph D, Bartholomew J, Sacha GL, et al. Coagulopathy in COVID-19: Manifestations and management. Cleve Clin J Med. 2020 Jul;87(8):461–8.
National Institute of Health. COVID-19 Treatment Guidelines 2 [Internet]. 2021 [dikutip 17 Nov 2021 Nov 17]. Tersedia dari: https://www.covid19treatmentguidelines.nih.gov/
Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Alcorn C, Kidwai-Khan F, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study. BMJ [Internet]. 2021 Feb 11 [Dikutip 12 Juli 2021];372. Tersedia dari: https://www.bmj.com/content/372/bmj.n311
Rentsch CT, Beckman JA, Tomlinson L, Gellad WF, Alcorn C, Kidwai-Khan F, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study. BMJ. 2021 Feb 11;372.
Salah HM, Mehta JL. 2021. Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19. Am J Cardiol [Internet]. 2021;142:158–9. Tersedia dari: https://doi.org/10.1016/j.amjcard.2020.12.073
Shen L, Qiu L, Liu D, Wang L, Huang H, Ge H, et al. 2021. The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19. Cardiovasc Drugs Ther.
Vajari MK, Shirin M, Pourbagheri-Sigaroodi A, Akbari ME, Abolghasemi H, Bashash D. COVID-19-related coagulopathy: A review of pathophysiology and pharmaceutical management. Cell Biol Int [Internet]. 2021 [dikutip 9 Agustus 2021];1–19. Tersedia dari: https://onlinelibrary.wiley.com/doi/full/10.1002/cbin.11623
Willim HA, Hardigaloeh AT, Supit AI. Koagulopati pada Coronavirus Disease -2019 ( COVID-19 ). Intisari Sains Medis. 2020;11(3):749–56.
World Health Organization. WHO Coronavirus (COVID-19) Dashboard, WHO Coronavirus (COVID-19) Dashboard [Internet]. Who. 2021 [dikutip 17 Sep 2021]. Tersedia: https://covid19.who.int/
Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, et al. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun. 2020 Dec 1;11(1).
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.